Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1

Conditions

Cholangiocarcinoma 2Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1

Interventions

Magnetic Resonance Spectroscopy 270Specimen Handling 259pembrolizumab 235Cyclophosphamide 220Radiotherapy 208Nivolumab 171Cisplatin 162Carboplatin 150Biopsy 148Radiosurgery 130fludarabine 125Blood Specimen Collection 117Gemcitabine 113Paclitaxel 111Surveys and Questionnaires 109Standard of Care 106venetoclax 97Dexamethasone 96Bevacizumab 95Radiation 88Rituximab 84Capecitabine 82Cytarabine 79Oxaliplatin 77Doxorubicin 76Drug Therapy 75durvalumab 73Ipilimumab 72fludarabine phosphate 69atezolizumab 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × pemigatinib × 90 days × Clear all
NCT07434843 2026-05-22

PEMIGIST

Dana-Farber Cancer Institute

Phase 2 Recruiting
24 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06302621 2026-05-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1 Recruiting
70 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06728410 2026-05-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Hoosier Cancer Research Network

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡